S&P 500   3,328.23 (-0.04%)
DOW   29,322.46 (-0.09%)
QQQ   223.62 (+0.11%)
AAPL   318.06 (-0.21%)
MSFT   167.51 (+0.25%)
GOOGL   1,484.71 (+0.35%)
AMZN   1,871.37 (+0.36%)
CGC   24.37 (-2.13%)
NVDA   249.06 (-0.09%)
BABA   221.86 (-2.45%)
MU   58.66 (+1.73%)
GE   11.74 (-0.59%)
TSLA   541.40 (+6.05%)
AMD   51.25 (+0.63%)
T   38.52 (+0.34%)
ACB   2.02 (-5.18%)
F   9.19 (+0.33%)
NFLX   336.22 (-1.02%)
DIS   143.99 (-0.24%)
S&P 500   3,328.23 (-0.04%)
DOW   29,322.46 (-0.09%)
QQQ   223.62 (+0.11%)
AAPL   318.06 (-0.21%)
MSFT   167.51 (+0.25%)
GOOGL   1,484.71 (+0.35%)
AMZN   1,871.37 (+0.36%)
CGC   24.37 (-2.13%)
NVDA   249.06 (-0.09%)
BABA   221.86 (-2.45%)
MU   58.66 (+1.73%)
GE   11.74 (-0.59%)
TSLA   541.40 (+6.05%)
AMD   51.25 (+0.63%)
T   38.52 (+0.34%)
ACB   2.02 (-5.18%)
F   9.19 (+0.33%)
NFLX   336.22 (-1.02%)
DIS   143.99 (-0.24%)
S&P 500   3,328.23 (-0.04%)
DOW   29,322.46 (-0.09%)
QQQ   223.62 (+0.11%)
AAPL   318.06 (-0.21%)
MSFT   167.51 (+0.25%)
GOOGL   1,484.71 (+0.35%)
AMZN   1,871.37 (+0.36%)
CGC   24.37 (-2.13%)
NVDA   249.06 (-0.09%)
BABA   221.86 (-2.45%)
MU   58.66 (+1.73%)
GE   11.74 (-0.59%)
TSLA   541.40 (+6.05%)
AMD   51.25 (+0.63%)
T   38.52 (+0.34%)
ACB   2.02 (-5.18%)
F   9.19 (+0.33%)
NFLX   336.22 (-1.02%)
DIS   143.99 (-0.24%)
S&P 500   3,328.23 (-0.04%)
DOW   29,322.46 (-0.09%)
QQQ   223.62 (+0.11%)
AAPL   318.06 (-0.21%)
MSFT   167.51 (+0.25%)
GOOGL   1,484.71 (+0.35%)
AMZN   1,871.37 (+0.36%)
CGC   24.37 (-2.13%)
NVDA   249.06 (-0.09%)
BABA   221.86 (-2.45%)
MU   58.66 (+1.73%)
GE   11.74 (-0.59%)
TSLA   541.40 (+6.05%)
AMD   51.25 (+0.63%)
T   38.52 (+0.34%)
ACB   2.02 (-5.18%)
F   9.19 (+0.33%)
NFLX   336.22 (-1.02%)
DIS   143.99 (-0.24%)
Log in

NASDAQ:EYEN - Eyenovia Stock Price, Forecast & News

$4.62
-0.11 (-2.33 %)
(As of 01/21/2020 12:56 PM ET)
Today's Range
$4.62
Now: $4.62
$4.73
50-Day Range
$3.23
MA: $3.97
$4.92
52-Week Range
$2.55
Now: $4.62
$6.98
Volume335 shs
Average Volume73,748 shs
Market Capitalization$75.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.43 per share

Profitability

Net Income$-17,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$75.95 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.


Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.05. View Eyenovia's Earnings History.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Eyenovia.

What price target have analysts set for EYEN?

2 equities research analysts have issued 1 year price objectives for Eyenovia's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Eyenovia's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 105.6% from the stock's current price. View Analyst Price Targets for Eyenovia.

What is the consensus analysts' recommendation for Eyenovia?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

Has Eyenovia been receiving favorable news coverage?

Media coverage about EYEN stock has trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyenovia earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Eyenovia.

Are investors shorting Eyenovia?

Eyenovia saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 280,300 shares, a decrease of 16.8% from the December 15th total of 336,700 shares. Based on an average daily volume of 94,500 shares, the short-interest ratio is presently 3.0 days. Currently, 2.9% of the shares of the stock are sold short. View Eyenovia's Current Options Chain.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the folowing people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $4.62.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $75.95 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

What is Eyenovia's official website?

The official website for Eyenovia is http://www.eyenoviabio.com/.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]


MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: volatile stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel